Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-09-15 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
109年04月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor presentation meeting, including date, time, location, and links to presentation materials. It specifically mentions a '法人說明會' which translates to 'investor presentation' or 'analyst meeting'. The content includes links to presentation PDFs and a webcast link, indicating this is material related to an investor presentation event rather than a full financial report or earnings release. The document length is short (827 characters) and it is essentially an announcement or summary of an investor presentation event. Therefore, the most appropriate classification is Investor Presentation (IP).
2021-09-15 Chinese
109年03月法人說明會簡報 — 179520210915E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'FY2019 RESULTS Investor presentation' and contains detailed financial results for the fiscal year 2019, including revenue, operating income, net income, EPS, and segment breakdowns. It also discusses strategic initiatives for FY2020, R&D pipeline, market share data, and other operational highlights. The document is structured as a presentation with slides and charts, typical of investor presentations. It is not a full annual report (10-K) as it lacks comprehensive financial statements and notes, nor is it a simple earnings release since it provides more detailed strategic and operational information. It is not an announcement or certification but a detailed presentation aimed at investors summarizing financial results and future plans. Therefore, the document fits best under the category 'Investor Presentation' (IP). The document length (10851 characters) supports it being a full presentation rather than a brief announcement.
2021-09-15 Chinese
109年03月法人說明會簡報 — 179520210915M001.pdf
Annual Report Classification · 95% confidence The document is titled 'FY2019 營運成果報告' which translates to 'FY2019 Operational Results Report'. It contains detailed financial performance data for the fiscal year 2019, including revenue, gross profit, operating income, net income, and EPS. It also discusses business achievements, strategic goals, product launches, R&D progress, and future outlook for 2020. The content is comprehensive and includes substantive financial data and analysis for the full fiscal year 2019. The document length is 8859 characters, which is sufficient to contain a full report rather than just an announcement. There is no indication that this is a certification, proxy, or announcement of a report. The detailed financial and operational information aligns with the characteristics of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K). FY 2019
2021-09-15 Chinese
109年03月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor relations event, specifically a '法人說明會' which translates to 'investor presentation' or 'analyst briefing'. It includes the company code, name, date and time of the event, location (online), a brief description indicating the company will explain its financial and operational status to institutional investors, and links to presentation materials and webcast. The content is clearly an investor presentation announcement or summary rather than a full financial report or transcript. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear keywords and format.
2021-09-15 Chinese
110年年報及股東會資料 — 2021_1795_20210617F14.pdf
Governance Information Classification · 95% confidence The document is titled '取得或處分資產處理程序' which translates to 'Procedures for Acquisition or Disposal of Assets' and contains detailed internal procedural rules regarding asset acquisition and disposal, including definitions, evaluation procedures, approval processes, risk management, and internal controls. It references compliance with regulatory standards and internal governance, including board and audit committee approvals. The document is a procedural guideline rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or executive changes. It is not a report publication announcement or a certification. It is a governance-related document detailing internal rules and processes for asset transactions and related risk management. Therefore, it fits best under Governance Information (CGR).
2021-09-14 Chinese
110年年報及股東會資料 — 2021_1795_20210617F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of the Annual General Meeting (AGM) of 美時化學製藥股份有限公司 for the year 110 (2021), including the agenda, attendance, reports presented, resolutions passed, and attachments such as the 109年度營業報告 (Annual Business Report for 2020), audit committee report, employee and director remuneration report, and private placement securities reports. The content includes detailed financial results, business plans, and discussions typical of an Annual Report. The presence of comprehensive financial data, management discussion, audit reports, and shareholder resolutions indicates this is the full Annual Report document rather than just an announcement or minutes. The document length (15,000 characters) and detailed financial tables further support this classification. Therefore, the document is best classified as an Annual Report (10-K). FY 2020
2021-09-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.